Axén Andreas, Andersson Hanna, Lindeberg Gunnar, Rönnholm Harriet, Kortesmaa Jarkko, Demaegdt Heidi, Vauquelin Georges, Karlén Anders, Hallberg Mathias
Department of Medicinal Chemistry, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.
J Pept Sci. 2007 Jul;13(7):434-44. doi: 10.1002/psc.859.
Angiotensin IV analogs encompassing aromatic scaffolds replacing parts of the backbone of angiotensin IV have been synthesized and evaluated in biological assays. Several of the ligands displayed high affinities to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. Displacement of the C-terminal of angiotensin IV with an o-substituted aryl acetic acid derivative delivered the ligand 4, which exhibited the highest binding affinity (K(i) = 1.9 nM). The high affinity of this ligand provides support to the hypothesis that angiotensin IV adopts a gamma-turn in the C-terminal of its bioactive conformation. Ligand (4) inhibits both human IRAP and aminopeptidase N-activity and induces proliferation of adult neural stem cells at low concentrations. Furthermore, ligand 4 is degraded considerably more slowly in membrane preparations than angiotensin IV. Hence, it might constitute a suitable research tool for biological studies of the (IRAP)/AT(4) receptor.
已合成了包含芳香骨架取代血管紧张素IV主链部分的血管紧张素IV类似物,并在生物学试验中进行了评估。其中几种配体对胰岛素调节氨肽酶(IRAP)/AT(4)受体表现出高亲和力。用邻位取代的芳基乙酸衍生物取代血管紧张素IV的C末端得到配体4,其表现出最高的结合亲和力(K(i)=1.9 nM)。该配体的高亲和力支持了血管紧张素IV在其生物活性构象的C末端采取γ-转角的假说。配体(4)抑制人IRAP和氨肽酶N活性,并在低浓度下诱导成年神经干细胞增殖。此外,配体4在膜制剂中的降解速度比血管紧张素IV慢得多。因此,它可能构成研究(IRAP)/AT(4)受体生物学的合适研究工具。